Track topics on Twitter Track topics that are important to you
TORONTO, Oct. 11, 2017 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that Dr. He...
Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results / Clinical responses observed in Phase 1 trial of TTI-621; Scope of trial expanded, including dose-intensification strategy; $39 million capital raise; cash and marketable
TORONTO, ONTARIO -- (Marketwired) -- 08/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
NewsTrillium has launched a discovery program that is focused on an undisclosed early-stage immuno-oncology target.
Trillium Therapeutics Inc TR Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by ...
TORONTO, ONTARIO -- (Marketwired) -- 10/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of c...
ALDEX GS™ Tablets
ALDEX GS DMTablets
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of innovative therapies for the treatment of ...
Trillium Medical Ventures, LLC, a bio science technology assessment firm founded in 1998, evaluates life science intellectual property and technology with the objective of identifying unique and valua...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...
We have published hundreds of Trillium Therapeutics Inc. news stories on BioPortfolio along with dozens of Trillium Therapeutics Inc. Clinical Trials and PubMed Articles about Trillium Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Trillium Therapeutics Inc. Companies in our database. You can also find out about relevant Trillium Therapeutics Inc. Drugs and Medications on this site too.